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Abstract
Objectives: To describe the use and evaluate the effectiveness of different lipid lowering therapies in unselected patients
with type 1 and type 2 diabetes in clinical practice.
Design: Observational population-based study using the personal identification number to link information from the
National Diabetes Register, the Prescribed Drug Register and the Patient register in Sweden. All patients in the NDR aged
18–75 years with diabetes more than one year were eligible, but only patients starting any lipid lowering treatment with at
least three prescriptions 1 July 2006–30 June 2007 were included (n=37182). The mean blood lipid levels in 2008 and
reductions in LDL cholesterol were examined.
Results: Blood lipid levels were similar in patients treated with simvastatin, atorvastatin and rosuvastatin, showing similar
lipid lowering effect as currently used. Users of pravastatin, fluvastatin, ezetimib and fibrate more seldom reach treatment
goals. Moderate daily doses of the statins were used, with 76% of simvastatin users taking 20 mg or less, 48% of atorvastatin
users taking 10 mg, 55% of pravastatin users taking 20 mg, and 76% of rosuvastatin users taking 5 or 10 mg.
Conclusions: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or
rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. There is potential to intensify lipid
lowering treatment to reduce the remaining high residual risk and achieve better fulfilment of treatment goals, since the
commonly used doses are only low to moderate.
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Introduction
Recent randomized clinical trials and a major meta-analysis
have emphasized the importance of LDL-cholesterol (LDL-C)
lowering for cardiovascular risk reduction in diabetes mellitus [1–
3]. Therefore the current treatment guidelines advocate aggressive
multifactorial risk factor intervention in patients with diabetes
[4,5]. The European guidelines promote lifestyle changes and lipid
lowering therapy in order to reach a lower LDL-C value than
2.5 mmol/L, or 1.8 mmol/L or lower if overt cardiovascular
disease (CVD) is present [5]. The pharmacological treatment
should be based on HMG CoA reductase inhibitors, also known as
statins, but other options are to be considered if the treatment
goals are not reached.
The LDL-C lowering effects of the different statins in clinical
trials have recently been reviewed [6]. A small or moderate dose of
statins could decrease LDL-C by 20–40%, with small differences
between the different agents. These conclusions are in agreement
with the CURVES and the STELLAR studies, in which
atorvastatin and rosuvastatin, respectively, showed similar effects
as other statin [7,8]. At higher doses, however, atorvastatin and
rosuvastatin are the only agents that can lower LDL-C more than
40% [6]. There have not been any randomized clinical trials or
observational epidemiological studies with head to head compar-
isons of the cholesterol lowering effect by different statins in
patients with diabetes.
The aim of this observational study linking data from the
Swedish National Diabetes Register (NDR), a quality register with
nation-wide coverage, with two other national population-based
registers, was to describe the use and evaluate the LDL-C lowering
effects of different lipid lowering therapies in 37 182 unselected
patients with type 1 and type 2 diabetes in clinical practice.
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This is a population-based study using the personal identifica-
tion number to link information from three national registers.
NDR was initiated in 1996 as a tool for quality improvement in
diabetes care, and has been described previously [9,10]. Physicians
and nurses in hospital outpatient clinics and primary health care
clinics report to the NDR at least once every year, either online or
by direct transfer of data from medical records databases. The
Swedish Prescribed Drug Register contains information about
dispensed prescribed drugs in the entire Swedish population of 9.4
million inhabitants [11]. The Swedish Patient Register contains
information on dates of hospital admission and discharge, codes
for all surgical procedures and discharge diagnoses [12,13]. The
Regional Ethical Review Board of the University of Gothenburg
approved the study, and all included patients have agreed to be
reported.
All patients aged 18–75 years in the NDR with diabetes for
more than one year were eligible, but only patients who had not
purchased any lipid lowering medicine 1 July 2005–30 June
2006 and thereafter filled at least three prescriptions 1 July
2006–30 June 2007 were included in the study (n=37 182].
These criteria were chosen based on the Swedish Pharmaceu-
tical Benefits Scheme where the patients normally fill a
prescription for 90 days of supply, and can refill again when
two thirds of the theoretical consumption time has passed. In
some cases the first filled prescription encompasses only a small
start package for 30 days of supply. Thus, those included in the
study would have purchased lipid lowering drugs corresponding
to seven months of use or more. Clinical characteristics
including mean blood lipid values on treatment (2008) were
studied in this group. We also performed a subgroup analysis of
patients who also had a known LDL-C value between 1 July
2005 and 30 June 2006), i.e., before the initiation of lipid
lowering therapy (n=10 456).
The clinical characteristics analysed at baseline were age, sex,
diabetes duration, BMI, smoking, blood pressure, HbA1c, total
cholesterol (TC), HDL-C, and serum triglycerides. The patients
were screened using local methods, but guidelines were available
to ensure the use of similar methodology. A smoker was defined as
a patient smoking one or more cigarettes per day, or a pipe daily,
or who had stopped smoking within the past three months. Renal
disease was defined as a history of acute, chronic, and any or
unspecified renal insufficiency.
Laboratory analyses, including TC and HDL-C levels, were
carried out at local laboratories. HbA1c analyses are quality assured
in Sweden by regular calibration with Mono-S, a HPLC method.
In this study, all HbA1c values were converted to the DCCT
(Diabetes Control and Complications Trial) standard levels:
HbA1c(DCCT)=0.9236HbA1c(Mono-S)+1.345; R
2=0.998 [14].
LDL-C was calculated using Friedewald’s formula [15] if serum TG
levels were lower than 4.0 mmol/L [16].
History of CVD recorded at hospital discharge was retrieved
from the Swedish Patient Register. CVD was defined as diagnosis
of myocardial infarction, angina pectoris, intracerebral haemor-
rhage, cerebral infarction or unspecified stroke before the survey,
but peripheral vascular disease was not included.
Statistical methods
General linear modelling was used to compare clinical
characteristics and reductions in LDL-C. The relative risks of
reaching LDL-C$2.5 mmol/L were estimated by using general-
ized linear modelling and simvastatin as the reference. When
adjusting for potential confounding factors, we categorised the
numeric variables: age (,30 years, 30–39 years, 40–49 years, 50–
59 years, $60 years), diabetes duration (,10 years, $10 years),
LDL-C level before taking statin (,2.5 mmol/L, $2.5 mmol/L).
Median doses of the lipid lowering agents were used as cut-offs in
these calculations (high dosages: simvastatin $20 mg, pravastatin
$40 mg, fluvastatin $40 mg, atorvastatin $20 mg, rosuvastatin
$10 mg as high dosage, fibrates $0.5 mg; all used 10 mg
ezetimib). In order to avoid a substantial reduction of the number
of subjects, we accepted ‘missing value’ of LDL-C as a single
category in our main analyses. All statistical analyses were
performed by use of SAS statistical software version 9.2 (SAS
Institute, Cary, NC, USA).
Results
Table 1 gives the clinical characteristics of the patients on any
lipid lowering treatment in 2008. Of all patients around 75% used
simvastatin, 14% used atorvastatin, 4% used pravastatin, 3% used
a statin plus ezetimib combination and 2% used a statin plus
fibrate combination. Fluvastatin, rosuvastatin and ezetemib were
used by 1% or less of the patients, respectively. The mean age was
around 62 years with almost 15 years of mean diabetes duration.
The proportion of men in the cohort was around 60%, circa 10%
had type 1 diabetes and 13% were smokers. Mean BMI was
almost 30 kg/m
2, mean blood pressure was 135/75 mm Hg and
HbA1c 6.4%. There were statistically significant differences
between mean values and proportions of all risk factors (except
diastolic blood pressure) in the different treatment groups and also
between the users of the different statins (except systolic and
diastolic blood pressure). A history of CVD was most common in
patients on pravastatin, fluvastatin or rosuvastatin. In patients on
simvastatin, a fibrate or combination therapy, a history of renal
disease was less common.
The numbers of patients and the proportion of patients
reaching LDL-C,2.5 mmol/L on the different doses of the
statins are given in Table 2. In patients with LDL-C,2.5 mmol/L
the distribution of doses were the same as in the overall cohort.
Only ezetimib 10 mg was used. In patients on fibrates, a daily dose
of 600 mg was the most common dose, used in 44% of these
patients. In statin plus ezetimib or fibrate combination therapy,
simvastatin was used in 64%, atorvastatin in 26%, pravastatin in
5% and rosuvastatin in 4%.
In Table 3 blood lipid values are given and the proportion of
patients achieving the current treatment goals. Figures 1, 2, 3, 4, 5,
6 presents the distribution of LDL-C values in patients on different
lipid lowering treatments. TC, LDL-C were lower and the
proportion of patients reaching the different treatment goals
highest in patients on simvastatin, atorvastatin, rosuvastatin or a
statin in combination with ezetimib or a fibrate. Consequently, the
proportion of patients reaching LDL-C,2.5 mmol/L and
#1.8 mmol/L (patients with a history of CVD) were highest
(57.4%–67.0% and 20.3%–28.9%, respectively) in these five
treatment groups. The group of patients on combination therapy
or on fibrates only exhibited the highest TG levels and lowest
HDL-C levels. The small group of patients on ezetimib only had
the highest TC and LDL-C. The proportion of patients not
reaching treatment goals of HDL-C were more than 60% in men
and around 80% in women, while TG targets were not reached in
40–50% of the patients on the most frequently used statins.
Patients with type 1 diabetes were generally treated with
simvastatin or atorvastatin (75% and 16%, respectively). The
numbers of patients on the other lipid lowering treatments were
very small (Table S1). In the simvastatin and atorvastatin
treatment groups blood lipid levels were very similar, and as
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LDL-C (2.460.7 mmol/L) was numerically almost the same, as
the overall cohort (2.360.7 mmol/L). In the patients with type 1
diabetes on simvastatin or atorvastatin, a history of CVD was less
common but a history of renal disease clearly more prevalent
(22.8% in simvastatin-treated patients and 32.4% in patients
taking atorvastatin) than the overall cohort, which mainly
consisted of patients with type 2 diabetes (79–89% in the different
treatment groups).
The mean effects on LDL-C levels after starting a lipid lowering
treatment in a subgroup of patients with an LDL-value both
before and during treatment are given in Table 4. The clinical
characteristics of these patients did not differ markedly from the
data presented in Table 1 and 3 (data not shown). The most
pronounced effects were seen in patients starting on simvastatin,
rosuvastatin, ezetimib or statin plus ezetimib combination.
Compared with the LDL-C levels before treatment, all changes
were statistically significant except for pravastatin and fluvastatin.
Table 5 gives the relative risks (and 95% confidence interval) of
achieving a LDL-C level $2.5 mmol/L in patients taking other
lipid lowering agents than simvastatin with those using simvastatin
as reference category. Without adjustment for covariates, dose and
LDL-C levels before the lipid lowering treatment, only atorvastatin
and rosuvastatin showed no difference in relative risk. The relative
risks were significantly higher than 1 in all other treatment groups.
An identical pattern was seen also after adjustment for the
covariates separately or all simultaneously, including doses of the
lipid lowering treatment and LDL-C before the treatment.
Table 1. Clinical characteristics of the patients on lipid lowering treatment 2008.
Variable Simvastatin Pravastatin Fluvastatin Atorvastatin
Rosuva-
statin Ezetimib Fibrate
Statin +
fibrate
Statin +
ezetimib
P-values:
overall
statins
Number of
patients
N 28025 940 159 5098 355 208 536 754 1107
Age Mean6SD 62.868.6 64.767.4 64.367.9 62.668.2 60.868.7 62.968.2 62.268.5 62.168.2 61.768.6 ,0.0001
,0.0001
Duration N 28025 940 159 5098 355 208 536 754 1107
Mean6SD 12.8611.5 14.2612.0 15.5613.7 14.5612.1 12.5611.4 15.5613.2 12.868.8 11.968.6 13.2612.1 ,0.0001
,0.0001
Men N 16444 519 102 3078 194 104 336 513 645
% 58.7 55.2 64.2 60.4 54.6 50.0 62.7 68.0 58.3 ,0.0001
0.0051
Type 1 diabetes N 2536 73 24 522 33 26 17 15 115
% 9.0 7.8 15.1 10.2 9.3 12.5 3.2 2.0 10.4 ,0.0001
0.0027
Type 2 diabetes N 23594 793 126 4148 291 167 465 671 897
% 84.2 84.4 79.2 81.4 82.0 80.3 86.8 89.0 81.0 ,0.0001
,0.0001
Systolic blood
pressure
N 27543 929 156 5011 348 204 530 736 1089
Mean6SD 136616 137616 137617 136616 135616 136616 138617 136617 135616 0.0103
0.106
Diastolic blood
pressure
N 27543 929 156 5011 348 204 530 736 1089
Mean6SD 75697 5 697 5 610 75697 5 610 76697 7 610 75697 5 69 0.1531
0.968
BMI N 26569 883 148 4814 335 198 502 714 1047
Mean6SD 29.665.1 29.665.0 29.364.8 29.965.1 30.065.0 29.464.9 30.265.0 30.864.8 30.164.9 ,0.0001
0.0002
Smokers N 3659 121 13 676 44 19 68 127 152
% 13.0 12.9 8.2 13.3 12.4 9.1 12.7 16.8 13.7 0.0348
0.0506
HbA1c N 27836 935 158 5072 354 208 531 748 1099
6.461.2 6.361.1 6.561.3 6.561.3 6.561.4 6.361.2 6.461.3 6.561.3 6.661.3 ,0.0001
,0.0001
CVD N 5567 258 44 1153 97 46 86 143 195
% 19.9 27.4 27.7 22.6 27.3 22.1 16.0 19.0 17.6 ,0.0001
,0.0001
Renal disease N 2472 107 39 641 48 29 37 63 99
% 8.8 11.4 24.5 12.6 13.5 13.9 6.9 8.4 8.9 ,0.0001
,0.0001
CVD, history of cardiovascular disease; Renal disease, history of renal disease. SD, standard deviation.
doi:10.1371/journal.pone.0018744.t001
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This observational study examining clinical use and the effects
on LDL-C levels of lipid lowering therapies shows that blood lipid
levels are very similar in patients treated with simvastatin,
atorvastatin and rosuvastatin in clinical practice in Sweden. These
three agents have also shown similar LDL-C lowering effects as
currently used. A combination with a statin and ezetimib or a
fibrate also shows similar effects, while users of pravastatin,
fluvastatin, ezetimib and fibrate more seldom reach recommended
TC and LDL-C levels. However, only moderate doses of the
different statins are used, with 76% of the patients on simvastatin
taking 20 mg or less daily, 48% of atorvastatin users taking 10 mg
daily, 55% of pravastatin users taking 20 mg daily, and 76% of
rosuvastatin users taking 5 or 10 mg daily.
The subgroup of patients with type 1 diabetes was characterized
by more renal disease but less history of CVD than the overall
cohort. These patients were mostly treated with simvastatin or
Table 2. Distribution of mean doses of the statins in patients on statins.
Substance Number (N) and proportion (%) Dose
5 m g 1 0 m g2 0 m g4 0 m g8 0 m g T o t a l N
Simvastatin N/% n.a. 5457 (19,5%) 15874 (56,6%) 6592 (23,5%) 102 (0,4%) 28025
% with LDL-C,2.5 mmol/L n.a. 3292 (18.4%) 10220 (57.2%) 4319 (24.1%) 50 (0.3%) 17881
Pravastatin N/% n.a. n.a. 515 (54,8%) 425 (45,2%) n.a. 940
% with LDL-C,2.5 mmol/L n.a. n.a. 218 (51.4%) 206 (48.6%) n.a. 424
Fluvastatin N/% n.a. n.a. 60 (37,7%) 47 (29,6%) 52 (32,7%) 159
% with LDL-C,2.5 mmol/L n.a. n.a. 16 (26.2%) 16 (26.2%) 29 (47.6%) 61
Atorvastatin N/% n.a. 2466 (48,4%) 1713 (33,6%) 415 (8,1%) 504 (9,9%) 5098
% with LDL-C,2.5 mmol/L n.a. 1606 (48.9%) 1103 (33.6%) 252 (7.7%) 319 (9.8%) 3280
Rosuvastatin N/% 17 (4,8%) 254 (71,5%) 75 (21,1%) 9 (2,5%) n.a. 355
% with LDL-C,2.5 mmol/L 13 (5.5%) 174 (73.1%) 47 (19.7%) 4 (1.7%) n.a 238
N.a., not applicable.
doi:10.1371/journal.pone.0018744.t002
Table 3. Blood lipid values of the patients on lipid lowering treatment 2008.
Variable Simvastatin
Prava-
statin
Fluva-
statin
Atorva-
statin
Rosuva-
statin Ezetimib Fibrate Statin + fibrate Statin + ezetimib
TC N 27887 933 158 5065 351 207 534 751 1097
Mean6SD 4.460.8 4.760.8 4.860.9 4.460.8 4.461.1 5.361.0 4.961.0 4.560.9 4.561.2
TC,4.5 N 15758 367 59 2938 201 44 185 378 589
% 56.5 39.3 37.3 58.0 57.3 21.2 34.6 50.3 53.7
LDL-C N 28025 940 159 5098 355 208 536 754 1107
Mean6SD 2.360.7 2.760.7 2.760.7 2.360.7 2.361.0 3.160.8 2.960.9 2.460.9 2.461.0
LDL-C,2.5 N 17881 424 61 3280 238 58 182 433 698
% 63.8 45.1 38.4 64.3 67.0 27.9 34.0 57.4 63.0
LDL-C#1.8 with
history of CVD
N 1526 30 4 310 33 2 7 39 67
% 25.9 32.2 25.0 25.7 28.9 25.0 12.1 21.08 20.3
HDL-C N 27769 927 159 5052 347 206 533 748 1090
Mean6SD 1.360.4 1.360.4 1.360.4 1.360.4 1.360.4 1.360.4 1.160.4 1.160.3 1.260.4
HDL-C.1.0 (men) N 10752 326 56 1819 117 65 136 196 381
% 38.7 35.2 35.2 36.0 33.7 31.6 25.5 26.2 35.0
HDL-C.1.3 (women) N 5849 194 28 898 66 54 61 59 205
% 21.1 20.9 17.6 17.8 19.0 26.2 11.4 7.9 18.8
TG N 27661 924 159 5036 346 207 533 749 1090
Mean6SD 1.760.9 1.760.8 1.860.9 1.860.9 1.961.0 1.861.0 2.161.2 2.461.3 2.161.2
TG,1.7 N 16309 493 82 2624 171 103 241 229 484
% 59.0 53.4 51.6 52.1 49.4 49.8 45.2 30.6 44.4
SD, standard deviation; TC, total cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides.
doi:10.1371/journal.pone.0018744.t003
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Figure 1. Histogram for the LDL-C values in patients on simvastatin.
doi:10.1371/journal.pone.0018744.g001
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doi:10.1371/journal.pone.0018744.g004
Figure 3. Histogram for the LDL-C values in patients on pravastatin.
doi:10.1371/journal.pone.0018744.g003
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doi:10.1371/journal.pone.0018744.g006
Figure 5. Histogram for the LDL-C values in patients on a fibrate.
doi:10.1371/journal.pone.0018744.g005
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cohort but had higher mean HDL-C and lower TG levels, as
expected.
Although around two thirds of the patients reach the overall
European and Swedish treatment goal of LDL-C,2.5 mmol/L,
many patients still have a high residual risk. The majority of
patients had HDL-C above target levels and almost half of the
population have elevated TG. Furthermore, in patients with a
history of CVD, more than 70% do not reach LDL-
C#1.8 mmol/L. The treatment targets were thus not sufficiently
achieved, particularly in the light of recently updated US and
European treatment guidelines from year 2007 with a recom-
mended goal for LDL-C of 2.5 mmol/L in patients with type 2
diabetes in general and 1.8 mmol/L in patients with a history of
CVD [4,5]. A slow improvement in overall risk factor control in
Swedish patients with type 2 diabetes and coronary heart disease
has been demonstrated, however, including an increased use of
lipid lowering agents over time, with a corresponding improve-
ment in blood lipid levels [17].
From 2003 and onwards generic simvastatin has been the first
line choice of lipid lowering therapy. Other agents could be used
when adverse effects appear, or if the individual treatment goals
are not met. In this study there were only minor differences in
patient characteristics between users of simvastatin, atorvastatin
and rosuvastatin, apart from a slightly higher prevalence of a
history of renal disease or CVD in the latter two. It is likely that a
history of co-morbidities in the patients was the basis for the choice
of statin in some cases, due to the presumed higher efficacy in
atorvastatin and rosuvastatin. Still, the LDL-C levels are not lower
than in patients taking simvastatin and the doses are low to
moderate, suggesting that lipid lowering therapy is currently not
consistent, and that a potential extra efficacy of atorvastatin or
rosuvastatin has not been made use of [7,8]. Furthermore, the
results of the multivariate analysis taking clinical characteristics
and LDL-C values before the treatment as well as doses of the
statins into account, suggest similar LDL-C lowering effectiveness
of these three agents. The weaker effects of pravastatin and
fluvastatin in this study are in agreement with previous reports
Table 4. LDL cholesterol values of patients on lipid lowering treatments before and on treatment in 2008.
Variable Simvastatin Pravastatin Fluvastatin
Atorva-
statin
Rosuva-
statin Ezetimib Fibrate
Statin +
fibrate
Statin +
ezetimib
Number of patients N 7975 260 33 1398 83 64 138 215 290
LDL-C before lipid lowering
treatment (mmol/L)
Mean6SD 2.660.9 2.760.7 2.760.8 2.460.8 2.661.0 3.360.9 3.060.9 2.560.9 2.861.1
LDL-C on lipid lowering
treatment (mmol/L)
Mean6SD 2.360.7 2.760.7 2.760.7 2.360.7 2.361.0 3.160.8 2.960.9 2.460.9 2.461.0
Change (mmol/L) Mean
(95% CI)
0.24
(0.22–0.26)
0.05
(20.02–0.13)
20.002
(20.18–0.17)
0.064
(0.02–0.10)
0.34
(0.12–0.56)
0.34
(0.10–0.59)
0.14
(0.01–0.27)
0.18
(0.07–0.29)
0.37
(0.25–0.49)
Change (%) Mean 9.2 1.9 0.1 2.7 13.1 10.3 4.7 7.2 13.2
P-value ,0.0001 0.1654 0.9754 ,0.0031 ,0.0024 0.0063 0.0270 0.0009 ,0.0001
SD, standard deviation; TC, total cholesterol; LDL-C, LDL cholesterol.
doi:10.1371/journal.pone.0018744.t004
Table 5. Relative risks and 95% confidence interval of lipid level $2.5 mmol/L in patients taking other lipid lowering agents than
simvastatin compared to taking simvastatin.
Simvastatin Pravastatin Fluvastatin Atorvastatin Rosuvastatin Ezetimib Fibrates
Model RR (95% CI)
Not adjusted Referent 1.52 (1.43–1.61) 1.70 (1.50–1.93) 0.99 (0.95–1.03) 0.91 (0.78–1.06) 1.99 (1.83–2.17) 1.82 (1.71–1.94)
Adjusted for:
Age Referent 1.54 (1.45–1.63) 1.69 (1.50–1.91) 0.98 (0.94–1.02) 0.90 (0.77–1.04) 1.96 (1.80–2.13) 1.79 (1.69–1.91)
Sex 1.50 (1.42–1.60) 1.71 (1.52–1.94) 0.99 (0.95–1.03) 0.91 (0.78–1.05) 1.97 (1.81–2.15) 1.83 (1.72–1.95)
Diabetes duration 1.52 (1.43–1.62) 1.71 (1.51–1.93) 0.99 (0.95–1.03) 0.90 (0.78–1.05) 2.02 (1.85–2.19) 1.84 (1.73–1.96)
Smoking 1.52 (1.43–1.61) 1.71 (1.51–1.93) 0.98 (0.95–1.02) 0.91 (0.78–1.06) 2.00 (1.83–2.18) 1.82 (1.71–1.94)
Dose 1.48 (1.39–1.57) 1.69 (1.49–1.91) 0.96 (0.92–1.00) 0.92 (0.79–1.07) - 1.77 (1.66–1.89)
LDL-C levels before treatment 1.49 (1.41–1.57) 1.68 (1.50–1.88) 1.01 (0.97–1.05) 0.90 (0.78–1.04) 1.73 (1.61–1.86) 1.68 (1.59–1.78)
CVD 1.53 (1.44–1.63) 1.72 (1.52–1.94) 0.99 (0.95–1.03) 0.92 (0.79–1.07) 2.00 (1.84–2.18) 1.79 (1.69–1.91)
Renal disease 1.52 (1.43–1.61) 1.75 (1.54–1.97) 0.99 (0.95–1.03) 0.91 (0.78–1.06) 2.01 (1.84–2.18) 1.81 (1.70–1.93)
Several variables* 1.55 (1.47–1.65) 1.75 (1.55–1.97) 1.00 (0.96–1.04) 0.90 (0.78–1.05) 2.01 (1.85–2.18) 1.78 (1.67–1.89)
Several variables# 1.52 (1.43–1.61) 1.74 (1.54–1.95) 0.98 (0.94–1.02) 0.91 (0.78–1.06) - 1.73 (1.62–1.84)
CVD, history of cardiovascular disease; Renal disease, history of renal disease. SD, standard deviation; RR, Relative risk; CI, Confidence intervals.
*Adjusted for age, duration of diabetes, smoking, CVD, renal diseases.
#Adjusted for age, duration of diabetes, smoking, LDL-level before the treatment, CVD, renal diseases.
doi:10.1371/journal.pone.0018744.t005
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the small sample sizes and possible selection effects. Overall, these
results from clinical practice verify a recent meta-analysis of
published randomized clinical trials, showing that the different
lipid lowering agents are equally efficacious at comparable doses
[6].
A possible contributory cause for the results of this study could
be the on-going discussion on the value of reaching certain
treatment lipid goals vs. standardized treatment with statins in risk
groups of patients, which could affect the prescribers. Major
clinical trials such as the Heart Protection Study [1] and the
Collaborative Atorvastatin Diabetes Study [2], underscored by the
results of the recent meta-analysis by the Cholesterol Treatment
Trialists’ (CTT) Collaborators [3], have shown secondary
preventive risk reduction after statin treatment also in patients
without pronounced hypercholesterolaemia. In order to reduce
CVD risk, however, the current US guidelines [4] promote statin
use in patients with diabetes and overt CVD, or in patients without
CVD who are older than 40 years and have one or more CVD risk
factors. Alternatively, a reduction in LDL-C of 30–40% could be
aimed at in patients not satisfactorily responding to a maximal
dose of statin. The European guidelines [5] similarly promote
LDL-C,2.5 mmol/L as the general treatment target in patients
with type 2 diabetes or type 1 diabetes with nephropathy, but also
give an opportunity for the clinician to offer statins in patients with
LDL-C,2.6 mmol/L.
The NDR has currently an estimated coverage of more than
90% of all patients in hospital outpatient clinics and more than
70% of all patients in primary care. The patients included in this
study are selected only based on completeness of the analysed
data, suggesting that they are indeed representative. There might
be minor errors in the clinical characteristics and risk factor values
from clinics where these are reported manually, but more and
more clinics transfer data automatically from computerized
medical records systems. There were, however, some expected
differences in mean levels and proportions of risk factors in the
different treatment groups, suggesting possible selection effects.
Therefore the results regarding blood lipid levels as well as the
LDL-C lowering effects of the different treatments should be
interpreted with some caution and should ideally be confirmed in
prospective clinical trials.
All information on the lipid lowering agents is retrieved from
Swedish Prescribed Drug Register, which contains complete
information about drug utilization in the entire Swedish
population [11]. We used strict criteria regarding the use of the
lipid lowering treatments, with only patients without former
purchases during a certain time period, followed by three
purchases during a specified period of time. We used the blood
lipid values reported after that period in our study, a technique
that could cause some errors. We determined, however, this to be
the best method to ensure the maximal number of patients in the
study, since blood lipid values are not measured frequently in
clinical practice, perhaps not more often than every second year in
most patients, and they are not likely to be reported to NDR more
than once every year.
In conclusion, this observational study shows that the LDL-C
levels in patients taking simvastatin, atorvastatin or rosuvastatin
are very similar as currently used, as well as their LDL-C lowering
effects. In order to achieve better fulfilment of treatment goals,
since the residual risk remains high in a large proportion of the
patients, there is a potential to increase the doses of the lipid
lowering treatments.
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